Biocryst Pharmaceuticals (BCRX) Short-term Investments (2010 - 2026)

Biocryst Pharmaceuticals has reported Short-term Investments for 17 years, with the latest figure at $66.8 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments fell 64.82% year-over-year to $66.8 million; the trailing twelve-month figure through Mar 2026 stood at $66.8 million (down 64.82% YoY), and the FY2025 full-year result was $185.0 million, down 14.4% from the prior year.
• Short-term Investments for Q1 2026 stood at $66.8 million, down from $185.0 million in the prior quarter.
• The five-year high for Short-term Investments was $278.3 million in Q4 2023, with the low at $48.0 million in Q1 2022.
• Historically, Short-term Investments has averaged $186.0 million across 5 years, with a median of $189.9 million in 2025.
• Annual changes were most pronounced in 2022 — Short-term Investments jumped 3621.76% — and 2026, when it tumbled 64.82%.
• Biocryst Pharmaceuticals' Short-term Investments stood at $119.5 million in 2022, then surged by 132.84% to $278.3 million in 2023, then retreated by 22.35% to $216.1 million in 2024, then declined by 14.4% to $185.0 million in 2025, then plunged by 63.89% to $66.8 million in 2026.
• The last three Short-term Investments figures came in at $66.8 million (Q1 2026), $185.0 million (Q4 2025), and $128.8 million (Q3 2025), per Business Quant data.